Drug Profile
BF 611
Latest Information Update: 30 Jan 2001
Price :
$50
*
At a glance
- Originator Fidia Farmaceutici
- Developer Bioiberica; Fidia Farmaceutici
- Class Anticoagulants; Antithrombotics; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Jan 2001 Discontinued-Preclinical for Thrombosis in Italy (Unknown route)
- 30 Jan 2001 Discontinued-Preclinical for Thrombosis in Spain (Unknown route)
- 18 May 1995 Preclinical development for Thrombosis in Italy (Unknown route)